(Q36635487)

15 August 2017

1 reference

title

Recent developments in decision-analytic modelling for economic evaluation (English)

1 reference

15 August 2017

1

Milton C Weinstein

1 reference

15 August 2017

publication date

1 January 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

24

1 reference

15 August 2017

issue

11

1 reference

15 August 2017

page(s)

1043-1053

1 reference

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness

15 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00019053-200624110-00002

Benefits due to immunization against measles

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00019053-200624110-00002

Probabilistic analysis and computationally expensive models: Necessary and required?

21 January 2018

1 reference

12 December 2020

The cost effectiveness of combination antiretroviral therapy for HIV disease.

1 reference

12 December 2020

Economic evaluation and decision making in the UK.

1 reference

12 December 2020

Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective

1 reference

12 December 2020

Empirically calibrated model of hepatitis C virus infection in the United States

1 reference

12 December 2020

Using value of information analysis to prioritise health research: some lessons from recent UK experience

1 reference

12 December 2020

Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model

1 reference

12 December 2020

Modeling for health care and other policy decisions: uses, roles, and validity

1 reference

12 December 2020

Markov chain Monte Carlo estimation of a multiparameter decision model: consistency of evidence and the accurate assessment of uncertainty.

1 reference

12 December 2020

Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy

1 reference

12 December 2020

Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis.

1 reference

12 December 2020

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

1 reference

12 December 2020

Foundations of Cost-Effectiveness Analysis for Health and Medical Practices

1 reference

12 December 2020

The Wisconsin Breast Cancer Epidemiology Simulation Model

1 reference

12 December 2020

Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis

1 reference

12 December 2020

Pertussis Vaccine — An Analysis of Benefits, Risks and Costs

1 reference

12 December 2020

Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis

1 reference

12 December 2020

Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.

1 reference

12 December 2020

Cost-effectiveness of treating multidrug-resistant tuberculosis

1 reference

12 December 2020

Cost-effectiveness of coronary artery bypass surgery

1 reference

12 December 2020

The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment

1 reference

12 December 2020

Expanded screening for HIV in the United States--an analysis of cost-effectiveness.

1 reference

12 December 2020

10.2165/00019053-200624110-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

15 August 2017

1052257873

0 references

1 reference